Variability in cardiac miRNA-122 level determines therapeutic potential of miRNA-regulated AAV vectors by Kraszewska, Izabela et al.
Original ArticleVariability in Cardiac miRNA-122
Level Determines Therapeutic Potential
of miRNA-Regulated AAV Vectors
Izabela Kraszewska,1 Mateusz Tomczyk,1 Kalina Andrysiak,1 Monika Biniecka,2 Anja Geisler,3 Henry Fechner,3
Michał Zembala,4 Jacek Ste
Î
pniewski,1 Józef Dulak,1,2 and Agnieszka Jazwa-Kusior1
1Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Kraków, Poland; 2Kardio-Med Silesia,
41-800 Zabrze, Poland; 3Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany; 4Department of
Cardiac Surgery, Heart and Lung Transplantation and Mechanical Circulatory Support, Silesian Center for Heart Diseases, 41-800 Zabrze, PolandSystemically delivered adeno-associated viral vector serotype 9
(AAV9) effectively transduces murine heart, but provides
transgene expression also in liver and skeletal muscles.
Improvement of the selectivity of transgene expression can be
achieved through incorporation of target sites (TSs) for
miRNA-122 and miRNA-206 into the 30 untranslated region
(30 UTR) of the expression cassette. Here, we aimed to generate
such miRNA-122- and miRNA-206-regulated AAV9 vector for
a therapeutic, heart-specific overexpression of heme oxygenase-
1 (HO-1). We successfully validated the vector functionality in
murine cell lines corresponding to tissues targeted by AAV9.
Next, we evaluated biodistribution of transgene expression
following systemic vector delivery to HO-1-deficient mice of
mixed C57BL/6J  FVB genetic background. Although AAV
genomes were present in the hearts of these animals, HO-1 pro-
tein expression was either absent or significantly impaired. We
found that miRNA-122, earlier described as liver specific, was
present also in the hearts of C57BL/6J  FVB mice. Various
levels of miRNA-122 expression were observed in the hearts
of other mouse strains, in heart tissues of patients with cardio-
myopathy, and in human induced pluripotent stem cell-derived
cardiomyocytes in which we also confirmed such posttranscrip-
tional regulation of transgene expression. Our data clearly
indicate that therapeutic utilization of miRNA-based regula-
tion strategy needs to consider inter-individual variability.Received 18 February 2020; accepted 7 May 2020;
https://doi.org/10.1016/j.omtm.2020.05.006.
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Nowadays, gene therapy is gradually emerging as one of the most
powerful strategies in the treatment of numerous inherited and ac-
quired disorders, including hemophilia, spinal muscular atrophy, or
Leber’s hereditary optic neuropathy (reviewed in Wang et al.1).
Even though various transgene delivery methods were developed, it
appears that vectors based on adeno-associated viruses (AAVs) are
the most successful so far, providing high expression of the therapeu-
tic gene with very limited immune response in the host organism.2
Still, the development of a therapy restricted to the selected organ
or cell type remains challenging in many cases. Although partial1190 Molecular Therapy: Methods & Clinical Development Vol. 17 June
This is an open access article under the CC BY-NC-ND license (htselectivity of the expression can be obtained through the utilization
of appropriate AAV serotype with tropism toward particular tissues,3
it is not sufficient to prevent all off-target effects associated with the
systemic delivery of the vector. Novel approaches aiming to overcome
this issue focus on the engineering of cell-type-specific AAV capsids
using directed evolution strategy; however, generation of such novel
vectors with sufficiently high infectivity is very laborious and
problematic in terms of specificity toward given cells and species.4
Sometimes it is possible to administer the vector directly to the chosen
tissue, i.e., into the cardiac muscle using a catheter-based electro-me-
chanical mapping and injection (NOGA) system.5 Nevertheless, this
route of delivery is invasive and can be hazardous to the patient,
especially considering coexisting disorders. Thus, the most desirable
cardiac gene therapy vector would be infused intravenously and
show efficient and selective gene transfer to the heart.
The majority of cardiac-muscle-targeting vectors are based on AAV
serotype 9 (AAV9) because it is the most efficient vector in in vivo
applications with described tropism toward murine heart, skeletal
muscles, and liver following systemic administration.6 Thus, in order
to further improve the vector properties and increase its cardiac spec-
ificity, additional regulatory mechanisms should be introduced. Un-
fortunately, incorporation of heart-specific promoters such as alpha
myosin heavy chain (a-MHC),7 myosin light chains (MLC2v),8 and
cardiac troponin T (cTnT)9 into the expression cassette does not pre-
vent vector leakage and transgene expression in other transduced tis-
sues, e.g., skeletal muscles or liver.10,11 Other shortcomings of such a
strategy may include a decreased level of transgene expression as
compared with the strong promoters of viral origin like cytomegalo-
virus (CMV).11 Hybrid promoters consisting of parts of CMV and eu-
karyotic promoters may help to overcome this issue; but on the other2020 ª 2020 The Author(s).
tp://creativecommons.org/licenses/by-nc-nd/4.0/).
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ward cardiomyocytes when compared with cardiac-specific promoter
alone.12 Generation of synthetic promoters combined with cardio-
myocyte-specific transcriptional cis-regulatory motifs allows for sig-
nificant improvement of transgene expression in the heart, but a
strong off-target effect was visible in the skeletal muscles.13
As an alternative to the above-mentioned approaches of targeting
transgene expression with cell-specific promoters, negative regulation
exploiting tissue specifically expressed miRNAs can be utilized. Incor-
poration of target sites (TSs) for chosen miRNA into the 30 untrans-
lated region (30 UTR) of the expression cassette enables posttranscrip-
tional regulation of transgene expression in a cell-specific manner.14
Thanks to RNA interference machinery, if a given miRNA is present
in the cells, vectors carrying corresponding TSs are silenced due to
degradation of the transgene mRNA or inhibition of translation pro-
cess.15 Such strategy was successfully applied for redirecting the
tropism of oncolytic viruses16 and numerous other studies, including
cell lineage tracking,17 detargeting of transgene expression from anti-
gen-presenting cells,18 or restricting the expression to specific cell
types, e.g., interneurons.19 In case of cardiac muscle, utilization of
three tandem repeats of TSs for miRNA-122 (highly expressed in
the liver) and genetically engineered TSs for miRNA-206 (referred
to as muscle-specific miRNA) in AAV9 vector resulted in efficient
transgene delivery to the heart with concomitant repression of its
expression in liver and skeletal muscles.20 In that study, male mice
of the BALB/c strain were used, and neither miRNA-122 nor
miRNA-206 was expressed in the hearts of these animals.20
Here, we aimed to utilize similar, miRNA-122 TS- and mutated
miRNA-206 TS-containing self-complementary AAV9 vector
(scAAV9-HO1-TS) for cardiac-specific expression of heme oxygen-
ase-1 (HO-1; HMOX1) gene. We and others have shown that this
stress-inducible enzyme involved in heme catabolism exerts impor-
tant cardioprotective effects after ischemic injury.21–23 First, the func-
tionality of scAAV9-HO1-TS vector was confirmed in vitro. Howev-
er, after its systemic administration to the animals lacking HO-1
(HO-1 knockout [KO]; C57BL/6J  FVB strain), there was almost
complete repression of transgene expression not only in the liver
and skeletal muscles but also in the heart. We found that this was
related to the presence of miRNA-122 in the hearts of these animals.
What is more, we detected this miRNA not only in the hearts of other
commonly used mouse strains but also of patients suffering from
various cardiomyopathies and in human cardiomyocytes derived
from induced pluripotent stem cells (iPSCs). Importantly, transduc-
tion of human iPSC-derived cardiomyocytes with miRNA-122-regu-
lated AAV, similarly to animal studies, resulted in considerable
reduction of transgene expression.
RESULTS
Assessment of Transgene Expression from the miRNA-122- and
miRNA-206-Regulated Vectors
In order to construct scAAV9 vectors for heart-specific overexpres-
sion of a chosen transgene, we have cloned human HO-1 codingMoleculasequence under the control of the CMV promoter into the previously
generated plasmid backbone containing three tandem repeats of TSs
for miRNA-122 and genetically engineered TSs for miRNA-206.20
miRNA-122 was previously described in several studies as liver spe-
cific,24,25 whereas utilization of the genetically engineered TSs for
the muscle-specific miRNA-206 was shown to abrogate its cross-reac-
tivity with miRNA-1 abundant in the heart.20 Thus, in our study, we
have used two miRNA-122- and miRNA-206-controlled constructs:
pdAAV-HO1-TS and control pdAAV-HO1-iTS with non-functional,
inverted miRNA TS (iTS) region for generation of the scAAV9
vectors (scAAV9-HO1-TS and scAAV9-HO1-iTS, respectively).
First, we evaluated the functionality of scAAV9 harboring the
HO1-TS or HO1-iTS expression cassette in HEK293 cells, which
are not only highly susceptible to AAV transduction but also do
not express any of the regulatory miRNAs (Figure 1A). As a positive
control, we used HO-1-carrying vector (scAAV9-HO1) devoid of
any miRNA TSs (Figures 1B and 1C). To facilitate transgene detec-
tion, we transferred HEK293 cells for 24 h to hypoxic conditions
(0.5% O2), because in human cells in hypoxia, endogenous HO-1
is downregulated by the Bach-1 repressor.26 Under hypoxic condi-
tions, transgene overexpression from both vectors was clearly visible
and comparable with control scAAV9-HO1 vector (Figures 1B and
1C), confirming the functionality of prepared constructs. In the next
step, the vectors were tested in various murine cell lines correspond-
ing to the tissues described as most efficiently transduced by system-
ically delivered AAV9.6We have chosen the AML-12 hepatocyte cell
line expressing miRNA-122, C2C12 myoblasts that acquire expres-
sion of miRNA-206 as they differentiate to myotubes, and the HL-1
cardiomyocyte cell line characterized by lack of both of those miR-
NAs (Figure 1A). Because some of the cell lines (HL-1, AML12, and
undifferentiated C2C12) turned out to be refractory to AAV9 trans-
duction, they were subjected to transfection only with the corre-
sponding plasmid. We observed considerably lower transgene
expression in AML-12 cells transfected with pdAAV-HO1-TS, in
comparison with the pdAAV-HO1-iTS with a non-functional regu-
latory region (Figure 1D). This effect was even more pronounced in
differentiated C2C12 cells, where HO-1 expression from the
scAAV9-HO1-TS vector was almost completely inhibited (Fig-
ure 1E). In contrast, in undifferentiated C2C12 myoblasts, in which
the miRNA-206 was barely detectable (Figure 1A), the level of HO-1
protein did not significantly differ between miRNA-regulated
pdAAV-HO1-TS and control pdAAV-HO1-iTS plasmid transfec-
tion (Figure 1F). Finally, we confirmed the functionality of the
HO1-TS expression cassette in the transfected HL-1 cardiomyocyte
cell line (Figure 1G) lacking both regulatory miRNAs (Figure 1A)
and proceeded with the assessment of in vivo cardiac specificity of
constructed vectors.
Analysis of In Vivo Functionality of the scAAV9-HO1-TS Vector
The in vitro experiments demonstrated that AAV9 harboring
miRNA-122 TSs and genetically engineered miRNA-206 TSs
may provide heart-specific transduction. Thus, next, we systemi-
cally administered scAAV9-HO1-TS and scAAV9-HO1-iTSr Therapy: Methods & Clinical Development Vol. 17 June 2020 1191
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Figure 1. Transgene Expression from the miRNA-
122- andmiRNA-206-Regulated Vectors Is Inhibited
in Cell Lines Expressing theCorrespondingmiRNAs
(A) qPCR analysis of relative miRNA-122 expression in
different cell lines, normalized to U6 snRNA. Bars repre-
sent mean +/- SEM (n = 3-5) Representative western blot
analysis of HO-1 protein level in: (B) HEK293 cells 7 days
after transduction with scAAV9-HO1 (positive control) or
scAAV9-HO1-iTS, and hypoxic conditions (0.5% O2)
were applied 24 h before protein isolation; (C) HEK293
cells 7 days after transduction with scAAV9-HO1 (positive
control) or scAAV9-HO1-TS, and hypoxic conditions
(0.5% O2) were applied 24 h before protein isolation; (D)
AML12 cells 72 h after transfection with pdAAV-HO-TS or
pdAAV-HO1-iTS plasmid; (E) differentiated C2C12 cells
7 days after transduction with scAAV9-HO-TS or
scAAV9-HO1-iTS vectors; (F) undifferentiated C2C12
cells 72 h after transfection with pdAAV-HO-TS or
pdAAV-HO1-iTS plasmid; and (G) HL-1 cells 72 h after
transfection with pdAAV-HO-TS or pdAAV-HO1-iTS
plasmid. All experiments were performed in duplicate and
were repeated at least three times. In all western blot
analyses, a-tubulin served as a loading control.
Molecular Therapy: Methods & Clinical Developmentvectors to 3-month-old HO-1 KO female mice of the C57BL/6J 
FVB strain. Then, after 4 weeks, the number of vector genome
copies, transgene mRNA, and protein level in the heart, liver,
and skeletal muscles were assessed. Genome copies (Figure 2A),
as well as the HO-1 transcript (Figure 2B) and protein (Figure 2C),
were detected in murine hearts and livers following scAAV9-HO1-
iTS administration. In skeletal muscles, the background signal (un-
treated mice) was very high, and thus prevented the estimation of
the number of AAV genome copies (Figure 2A); however, tran-
script and HO-1 protein were successfully detected (Figures 2B
and 2C, respectively). What is more, in agreement with previously
published data,20 transgene expression from scAAV9-HO1-TS was
completely repressed in the liver and skeletal muscles (Figure 2C),
while AAV genomes and transgene mRNA (Figures 2A and 2B,
respectively) were detected in those tissues, confirming successful
transduction. Surprisingly, we observed a similar effect of
scAAV9-HO1-TS in the heart, where despite the presence of
AAV genomes (Figure 2A), no HO-1 protein was produced (Fig-
ure 2C). Thus, in order to explain this observation, we analyzed
the expression of miRNA-122 in the hearts of these animals and
found that miRNA-122, described so far as liver specific, is also ex-
pressed in the hearts of female C57BL/6J  FVB mice (Figure 2D,1192 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020left panel, white bar). Still, its expression was
much lower than in the liver (Figure 2D, right
panel, white bar).
Because sex differences may exist in miRNA
profiles,27 we assessed the level of miRNA-122
also in the hearts of male mice of the C57BL/
6J  FVB strain. It was considerably lower
than in female mice (Figure 2D, left panel, blackbar) and again much lower than in liver (Figure 2D, right panel, black
bar), but still detectable. Of note, miRNA-122 expression in the heart
was not dependent on HO-1, because the same results were obtained
in wild-type animals (data not shown). In addition, we checked
miRNA-206 expression because its presence in the heart may also
cause the same off-target silencing; however, the level of this miRNA
was below the detection limit (data not shown).
Next, we wanted to verify whether a lower expression of miRNA-
122 in the hearts of male C57BL/6J  FVB mice (Figure 2D) will
result in a similar inhibition of transgene expression from the
miRNA-controlled vector as in female mice. For this reason, we
systemically administered scAAV9-HO1-TS and scAAV9-HO1-
iTS vectors to 3-month-old HO-1 KO male mice of the C57BL/
6J  FVB strain. We confirmed the presence of AAV genomes
in hearts and livers (Figure 2E) and the presence of transgene
mRNA (Figure 2F) in all analyzed tissues after delivery of both
vectors. Moreover, even though in the hearts of male mice HO-1
protein was detectable after administration of scAAV9-HO1-TS
vectors, we have noted a very potent (more than 10-fold) repres-
sion of transgene expression in comparison with the control
scAAV9-HO1-iTS vector (Figure 2G).
Figure 2. Transgene Expression from the miRNA-
122- andmiRNA-206-Regulated Vectors Is Inhibited
in Tissues Expressing the Corresponding miRNAs
(A–G) Female mice of C57BL/6J  FVB strain 4 weeks
after intravenous scAAV9 vectors administration (n = 3
mice/group): (A) qPCR quantification of scAAV genomes
based on copies of ITR region detected with qPCR using
TaqMan probe, normalized to 18S gene copies; (B) qPCR
analysis of human HO-1 (HMOX1) transcript level; (C)
ELISA for human HO-1 protein; (D) qPCR analysis of
relative miRNA-122 expression in hearts and livers of fe-
male and male mice of C57BL/6J  FVB strain, normal-
ized to U6 snRNA level. Male mice of C57BL/6J  FVB
strain 4 weeks after intravenous scAAV9 vectors admin-
istration (n = 3 mice/group): (E) qPCR quantification of
scAAV genomes based on copies of ITR region detected
with qPCR using TaqMan probe, normalized to 18S gene
copies; (F) qPCR analysis of human HO-1 (HMOX1 gene)
transcript level; and (G) ELISA for human HO-1 protein.
Bars represent mean ± SEM in all graphs.
www.moleculartherapy.orgProfiling of miRNA-122 Expression in the Hearts of Various
Mouse Strains and Patients Suffering from Cardiomyopathies
Previous studies utilized the miRNA-122-controlled vectors in
different mouse strains than ours: male BALB/c,20 male ICR,28 or
NMRI (information about sex was not provided).29 Thus, we decided
to investigate the miRNA-122 expression in the hearts of the mouse
strains most widely used in the animal experimentation, namely,
C57BL/6J, FVB, CBA, DBA, and BALB/c. In all cases, we used 3-
month-old animals. miRNA-122 was clearly detected in both female
andmale mice of the FVB strain (Figure 3A), with significantly higher
expression in females, similarly to our crossbred C57BL/6J  FVB
mice (Figure 2D). In male BALB/c mice, miRNA-122 level was low
but comparable with the level detected in male C57BL/6J  FVB
mice (Figure 3B). Apart from that, we were able to detect miRNA-Molecular Therapy: Methods &122 also in the hearts of male C57BL/6J, CBA,
and DBA mouse strains, as well as in outbred
animals (Figure 3B). Thus, strain-related vari-
ability of miRNA-122 level in mice was
considerable.
Next, we wanted to assess whether the data
from murine hearts could reflect the individual
differences in humans. For this purpose, we
used heart tissue of patients suffering from
various cardiomyopathies that was collected
during cardiac transplantation. It turned out
that miRNA-122 was detectable in all but one
heart tissue, and its level differed between pa-
tients (Figure 3C).
We also aimed to investigate the potential regu-
latory mechanisms underlying such consider-
able variability in miRNA-122 level in the heart.We focused on the description in the literature of the main transcrip-
tional regulators of this miRNA expression in the liver, including
hepatocyte nuclear factor (HNF) 1-alpha (HNF1a), HNF 3-alpha
(HNF3a), HNF 3-beta (HNF3b), HNF 4-alpha (HNF4a), and reti-
noic X receptor-alpha (RXRa; RXRA).30,31 Interestingly, the tran-
scripts encoding all of these factors were present in the hearts of
FVB, C57BL/6J, C57BL/6J  FVB, and BALB/c mice; however, the
expression was uniform among investigated strains (data not shown).
In the clinical samples, we detected greater variability in cardiac
expression of HNF1a (Figure 3D), HNF3b (Figure 3E), and RXRA
(Figure 3F). Interestingly, the profile of RXRA expression (Figure 3F)
to some extent corresponded with miRNA-122 (Figure 3C), suggest-
ing a possible regulatory mechanism of this miRNA expression in
the human heart.Clinical Development Vol. 17 June 2020 1193
Figure 3. Cardiac miRNA-122 Expression Varies
between Various Mouse Strains and between
Human Individuals
(A–C) qPCR analysis of miRNA-122 expression in (A)
hearts of female and male mice of FVB strain (n = 5 mice/
group), (B) hearts of male mice of various strains (n = 5 of
FVB, outbred, C57Bl6/J, DBA, C57BL/6J  FVB, BALB/
c mice/group; n = 3 of CBA mice/group), and (C) heart
tissues collected from patients suffering from different
cardiomyopathies. (D–F) qPCR analysis of (D) HNF1a, (E)
HNF3b, and (F) RXRA expression in heart tissues
collected from patients suffering from different cardio-
myopathies. Bars represent mean ± SEM in all graphs.
Sample description: F, female; M, male; number, age of
the patient undergoing heart transplantation.
Molecular Therapy: Methods & Clinical DevelopmentAnalysis of miRNA-Regulated Vector Functionality in Human
Cardiomyocytes
Finally, we aimed to analyze whether transgene expression in human
cardiomyocytes may be subjected to, similar as in animal studies,
miRNA-122-mediated posttranscriptional regulation. Due to a well-
known difficulty in obtaining primary human cardiomyocytes and
their very limited proliferation potential,32,33 for this purpose we uti-
lized human iPSC-derived cardiomyocytes. First of all, we detected
miRNA-122 in the cells from all three healthy donors (Figure 4A).
Next, these iPSC-derived cardiomyocytes were transduced with
scAAV9-GFP-TS and scAAV9-GFP-iTS. Here, the HO-1 harboring
vectors were replaced with GFP-expressing ones to avoid a possible
influence of endogenous HO-1 expression and its variability between
different donors on the final outcome. Additionally, because cardio-
myocytes were derived from different donors, we wanted to minimize
the effect of potential variations in AAV9 receptor availability on the
transduction efficiency. Thus, before transduction, cardiomyocytes
were treated with neuraminidase to expose N-linked galactose on
the surface of the cells, which is the primary receptor for AAV9.34
The level of miRNA-122 was relatively low in all three lines of human
iPSC-derived cardiomyocytes (Figure 4A), but it was still sufficient to
effectively inhibit transgene expression, because both the percentage1194 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020of GFP+ cells (Figure 4B) and median fluores-
cence intensity (MFI) (Figure 4C) following
scAAV9-GFP-TS were approximately by half
smaller than after control scAAV9-GFP-iTS
vector transduction.
DISCUSSION
Despite numerous successful applications of
gene therapy developed in recent years, many
aspects regarding the design of safe and effective
vectors remain challenging. One of these con-
cerns is specific transgene delivery to the chosen
tissues. Although wide tropism of some AAV
vectors facilitated their potential application
in the treatment of many diseases, it may be
considered also as one of their shortcomings.Off-target transduction might not only disrupt the homeostasis of
cells unaffected by a given disease but also contribute to the develop-
ment of immune response against delivered transgene (reviewed in
Boisgerault and Mingozzi35). Such an effect was already observed in
some studies involving in vivo AAV-mediated transgene introduc-
tion. Although expression of the transgene in the liver is mostly asso-
ciated with tolerogenic response,36 in the skeletal muscles it is likely to
induce transgene-specific CD8+ T cell infiltration into the tissue.37,38
In case of cardiac muscle, very efficient gene delivery can be achieved
using AAV serotype 9; however, transduction will occur also in the
liver and skeletal muscles.3 To restrict transgene expression only to
the heart, the expression cassette may contain regulatory sequences
responding to endogenously expressed miRNAs. Previous studies
have shown that incorporation of tandem repeats of liver-specific
miRNA-122 TSs and skeletal muscle-specific miRNA-206 genetically
modified TSs into the 30 UTR of expression cassette allows for post-
transcriptional de-targeting of transgene expression from these tis-
sues, and thus for the generation of heart-specific AAV9 vec-
tors.20,28,29 In our study, we have confirmed the functionality of the
HO1-TS and HO1-iTS expression cassettes in various cell lines,
showing that the expression of the transgene is indeed dependent
Figure 4. Transgene Expression from the miRNA-
122- andmiRNA-206-Regulated Vectors Is Inhibited
in Human iPSC-Derived Cardiomyocytes
(A) qPCR analysis of relative miRNA-122 expression in
human iPSC-derived cardiomyocytes from three different
iPSC donors. (B and C) Flow cytometric analysis of (B)
percentage of GFP-expressing cells and (C) median
fluorescence intensity (MFI) 96 h after transduction of
human iPSC-derived cardiomyocytes with scAAV9-GFP-
TS or scAAV9-GFP-iTS vectors. All experiments were
performed in duplicate. Bars represent mean ± SD in all
graphs.
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Importantly, the HL-1 cardiomyocyte cell line did not contain any
of these miRNAs, and consequently transgene was expressed after
transfection with both iTS- and TS-carrying vectors. Surprisingly,
when we intravenously administered scAAV9-HO1-TS to HO-1
KO female mice, we did not detect HO-1 protein in the hearts of these
animals, despite the presence of scAAV genomes and transgene
mRNA in the tissue. This result was in striking contrast with other
studies showing that incorporation of the target sequence of
miRNA-122 into the 30 UTR of the expression cassette led to heart-
specific transgene expression.28,29,39
As the major difference between current and previously published
data, we have identified the strain of mice (C57BL/6J  FVB versus
BALB/c, ICR, NMRI or Ai9  C57BL/6). We detected considerable
expression of miRNA-122 in the hearts of our C57BL/6J  FVB fe-
male mice, which resulted in complete repression of transgene expres-
sion in this tissue following application of scAAV9-HO1-TS vectors.
In some of the previous studies, male mice were used; thus, taking into
account that sex differences may determine the miRNA profile,27 we
checked the miRNA-122 expression also in male C57BL/6J  FVB
mice and found that it was significantly lower than in females. This,
however, also resulted in substantial, although not complete, repres-
sion of transgene expression in the heart following systemic scAAV9-
HO1-TS vectors administration. Still, we cannot exclude that other
factors apart from miRNA-122, e.g., hormones, may influence the ef-
ficiency of transgene expression and partially contribute to the
observed discrepancies between male and female mice.
The analysis of miRNA-122 expression in the hearts of male mice of
various strains revealed substantial differences. We detected relatively
high levels of this miRNA in the hearts of a few commonly used
mouse strains, including FVB, C57BL/6J, DBA, and CBA. Moreover,Molecular Therapy: Methods &even though the level of cardiac miRNA-122 in
male C57BL/6J  FVB and BALB/c mice was
comparable and the lowest among all analyzed
mouse strains, in contrary to previously pub-
lished data,20,29 we observed partial repression
of the transgene in the heart. The main factor
accounting for that outcome may be very high
sensitivity of the regulatory system to anychanges in miRNA-122 due to the presence of tandem repeats of
the TS region.40 Furthermore, the sensitivity of the miRNA-driven
regulation is also influenced by the surrounding sequences and the
proximity of TSs to the STOP codon of the transgene coding
sequence,41 which differ between ours and previous studies. Another
factor that may contribute to the observed discrepancies between the
studies on miRNA-122-regulated vectors may be the age of the ani-
mals used in the experiments. Whereas BALB/c mice utilized previ-
ously were around 6 weeks old,20 here we analyzed 3-month-old an-
imals. Although this difference seems to be quite low, our results
suggest that miRNA-122 expression in the heart of some mouse
strains may increase with the age of the animal (unpublished data).
Apart from that, we should also take into consideration that different
sources of mice used in the experiments might introduce additional
fluctuations.
Importantly, here we demonstrate that similar variability in cardiac
miRNA-122 expression may exist also in humans. Several studies
described miRNA-122 as liver specific because of high expression
in this organ.25,42 Interestingly, the plasma level of this miRNA was
remarkably upregulated in patients with hyperlipidemia compared
with healthy controls, and it was closely associated with the presence
and the severity of coronary heart disease (CHD) in hyperlipidemia
patients.43 A recent meta-analysis demonstrated stable changes of
miRNA-122-5p in CHD subjects, indicating that it may be a poten-
tially useful therapeutic target.44 Although miRNA-122 expression
is the highest in liver, it was also detected in the nervous and respira-
tory systems.25 Here we show that miRNA-122 is present also in the
hearts of patients suffering from various cardiomyopathies. In the
future, having the opportunity to analyze a larger group of patients,
it might be worth it to correlate this miRNA expression profile with
age, sex, or particular disease. If a specific disorder could influence
miRNA-122 level in the heart, it would also determine theClinical Development Vol. 17 June 2020 1195
Molecular Therapy: Methods & Clinical Developmenteffectiveness of gene therapy with miRNA-regulated AAV. Although
very limited, there is some evidence supporting the role of miRNA-
122 in the regulation of cardiomyocyte apoptosis influencing the
expression of caspase-8.45,46 Interestingly, an increase in miRNA-
122 in rat cardiomyocytes was induced by hypoxia/reperfusion,
demonstrating its potential role in cardiac pathologies.47
Transcriptomic and proteomic analyses included in Human Protein
Atlas (https://www.proteinatlas.org/) provide data supporting the
presence of several potential positive regulators of miRNA-122 level
in the human heart, including HNF4a and RXRa. Moreover, accord-
ing to Expression Atlas (http://www.ebi.ac.uk/gxa), Hnf4a and Rxra
are also expressed in murine heart. Although we confirmed the pres-
ence of Hnf1a, Hnf3a, Hnf3b, Hnf4a, and Rxra in the hearts of
various mouse strains, there were no significant differences in their
expression (data not shown). In contrast, patient samples exhibited
more variability, and particularly the expression of RXRA to some
extent corresponded with the expression of miRNA-122. Obviously,
because these factors were described as miRNA-122 expression regu-
lators in the liver,30,31 interpretation of our data in the heart is more
complex, because different, yet unknown, regulatory pathways can
be involved. Still, it is important that HNFs are expressed in
cardiac tissue and consequently might influence the expression of co-
existing genes or miRNAs. This, however, would require further
investigation.
In this study, we also tested human cardiomyocytes obtained from
iPSCs in terms of potential miRNA-122-mediated posttranscriptional
regulation of transgene expression. Human iPSC-derived cardiomyo-
cytes are used in basic and translational cardiac research tomodel car-
diovascular diseases, study drug toxicity, and advance potential
regenerative therapies.48,49 They are also susceptible to AAV9 trans-
duction. Even though miRNA-122 level was relatively low in human
cardiomyocytes derived from all three iPSC cell lines, similar to ani-
mal studies, we observed downregulation of transgene expression
following transduction with miRNA-122-regulated AAV9 in com-
parison with control vector with inverted TS region. These data
further underline the significance of miRNA-122 expression in the
heart and its impact on the final outcome of the therapy utilizing
miRNA-regulated vectors. On the other hand, it should also be
considered that iPSC-derived cardiomyocytes exhibit rather imma-
ture phenotype, when compared with adult cardiomyocytes, and
are functionally closer to prenatal cardiomyocytes.50,51 This feature
may contribute to the low miRNA-122 expression in our iPSC-
derived cardiomyocytes. Previous study by Kuppusamy et al.52
demonstrated that miRNA-122 was one of the significantly upregu-
lated miRNAs in conditioned engineered heart tissue when compared
with 1-year matured human embryonic stem cell-derived cardiomyo-
cytes, indicating a possible regulation of this miRNA during cardio-
myocyte maturation. Thus, in the future, a long-term culture of
iPSC-derived cardiomyocytes and other treatments that improve
their maturity52 can be applied to increase the translational potential
of these cells. Subsequent investigation and comparison of the
miRNA expression profile of such mature cardiomyocytes with pri-1196 Molecular Therapy: Methods & Clinical Development Vol. 17 Junemary human cardiomyocytes could create new opportunities in
screening patients for miRNA-regulated therapy.
In summary, our data indicate high sensitivity of the miRNA-regula-
tory system to any variations in the corresponding endogenous
miRNA expression. This underlines the importance of choosing the
appropriate animal model for the preclinical evaluation of therapy
effectiveness, as in some cases the final results may be heavily influ-
enced by the genetic background. Moreover, inter-individual differ-
ences in the human cardiac miRNA-122 expression raise some doubts
regarding widespread clinical application of such regulation strategy.
Even though there might be a fraction of patients who could poten-
tially benefit from such therapy utilizing miRNA-122-regulated
AAV vectors, qualification of patients based on prior non-invasive
assessment of the miRNA-122 level in the heart would be necessary.
MATERIALS AND METHODS
Animals
BALB/c, DBA, CBA, and outbred mice were acquired from the
breeding colony at the Institute of Zoology of Jagiellonian University
(Krakow, Poland). C57BL/6J and FVB mice were obtained from a
breeding colony at the Mossakowski Medical Research Centre, Polish
Academy of Sciences (Warsaw, Poland).Hmox1/C57BL/6J FVB
mice (HO-1 KO) were generated at the Faculty of Biochemistry,
Biophysics and Biotechnology, Jagiellonian University (Krakow,
Poland) from the Hmox1+/ heterozygous breeding pairs kindly
gifted by Dr. Anupam Agarwal (Birmingham, AL, USA). All mice
used in the experiments were 3 months old. All animal procedures
were conducted in accordance withGuide for the Care and Use of Lab-
oratory Animals (Directive 2010/63/EU of European Parliament) and
carried out under a license from the Ethical Committee of the Jagiel-
lonian University. Animals were maintained under controlled envi-
ronmental conditions (12-h light/dark cycle, at approx. 23C) and
provided with standard laboratory food and water ad libitum.
Construction of Plasmids
Plasmids for production of scAAV9 vectors regulated by miRNA-122
and miRNA-206 expression were prepared using Gibson Assembly
Master Mix (catalog [cat.] #E2611; NEB, Ipswich, MA, USA) through
replacement of S100A coding sequence with the sequence encoding
human HO-1 in previously cloned and described plasmids:
pscAAV-CMV-MLC0.26-NFS100A1miR-122(3x)TS/m206(3x)TS-3G. with
miRNA-122 TS and mutated miRNA-206 TS or pscAAV-CMV-
MLC0.26-NFS100A1invTS, where the TS region of both miRNAs
has been inverted and thus non-functional.20 In addition, instead of
the hybrid CMV-MLC0.26 promoter, we utilized the CMV promoter.
In this manner we have generated, respectively, pdAAV-CMV-HO1-
TS (pdAAV-HO1-TS) and pdAAV-CMV-HO1-iTS (pdAAV-HO1-
iTS) plasmids for scAAV9 production. Similar constructs were pre-
pared with GFP transgene under the control of a CMV promoter:
pdAAV-CMV-GFP-TS (pdAAV-GFP-TS) and pdAAV-CMV-GFP-
iTS (pdAAV-GFP-iTS). Primers with specific adapters that enabled
assembly were designed using NEBulider Assembly Tool. Schematic
representation of plasmidmaps was generated with SnapGene Viewer2020
www.moleculartherapy.orgSoftware (plasmid map is available in the Supplemental Information;
Figure S1). Following cloning steps, all plasmids were subjected to
Sanger sequencing to ensure correct insertion of the transgene.
Production of AAV Vectors
The scAAV9 vectors were produced in a helper-free, three-plasmid
system using CellRoll Bottle Roller (Integra Biosciences, Zizers,
Switzerland). For this purpose, AAV293 packaging cells (HEK293
subclone) were seeded on collagen-coated Roller Bottles (cat.
#431198; Corning, NY, USA) and cultured until they reached 50%–
60% confluence. Next, the cells were transfected with 130 mg pHelper
(Stratagene, San Diego, CA, USA), 100 mg p5E18VD2/9 (kindly pro-
vided by Prof. James Wilson, University of Pennsylvania, Philadel-
phia, PA, USA), and 90 mg pdAAV-CMV-HO1 (without any miRNA
TS), pdAAV-CMV-HO1-TS, pdAAV-CMV-HO1-iTS, pdAAV-
CMV-GFP-TS, or pdAAV-CMV-GFP-iTS plasmids utilizing PEI
MAX (cat. #24765; Polysciences, Warrington, PA, USA) as a transfec-
tion reagent (2.58 mg/mL; 1 mL per 1 mg DNA). After 72 h, cells were
detached from the culture surface, centrifuged, and lysed through
three freeze-thaw cycles in liquid nitrogen and 37C water bath.
Then, lysates were digested with HS nuclease (cat. #GE-
NUC10700-01; MoBiTec, Göttingen, Germany) in a final concentra-
tion of 50 U/mL for 1 h at 37C and subsequently precleared by
centrifugation for 30 min at 4,000  g, 4C. Precleared lysates were
further purified though ultracentrifugation (300,000  g, 2 h, 18C)
on discontinuous iodixanol gradient (gradient composition: 17 mL
of processed crude lysate, 6 mL of 15% iodixanol, 4.5 mL of 25% io-
dixanol, 3.5 mL of 40% iodixanol, and 3.5 mL of 54% iodixanol). Io-
dixanol dilutions were prepared in PBS with 0.5 mM MgCl2 and
2.5 mM KCl. After ultracentrifugation, 40% iodixanol fraction con-
taining AAV vectors was collected and was further concentrated on
Amicon Ultra-15 Centrifugal Filters (cat. #UFC910024; 100 kDa;
Merck Millipore, Burlington, MA, USA).
Next, using phenol-chloroform extraction, we isolated DNA from a
small portion of purified vectors to quantify the number of viral ge-
nomes (vg). Titration of AAV genome copies was carried out using
quantitative PCR (qPCR) with inverted terminal repeat (ITR)-bind-
ing TaqMan probe with serial dilutions of linearized plasmid as
standard curve. qPCR was prepared using TaqMan Gene Expression
Master Mix, according to the manufacturer’s instructions with
specific primers and TaqMan probe in a final concentration of
100 nM (For [Forward]: 50 CGGCCTCAGTGAGCGA; Rev [Reverse]:
50-GGAACCCCTAGTGATGGAGTT; Probe: 50-6-FAM-CACTCC
CTCTCTGCGCGCTCG-BHQ-1).
Cell Culture, Transfection, and Transduction Assays
HEK293 and mouse C2C12 cells (ATCC, Manassas, VA, USA) were
cultured in DMEM high-glucose medium supplemented with 10%
fetal bovine serum (FBS) and antibiotics (penicillin 100 U/mL, strep-
tomycin 100 mg/mL). Differentiation of C2C12 cells to myotubes was
carried out for 5 days in the conditions of reduced growth factors
availability, where FBS in the culture medium was replaced by 2%
horse serum.53 HL-1 mouse cardiac myocytes (cat. #SCC065;MoleculaSigma-Aldrich, Saint Louis, MO, USA) were cultured in Claycomb
medium (cat. #51800C; Sigma-Aldrich) supplemented with 10%
FBS, GlutaMAX I CTS (cat. #A1286001; GIBCO), norepinephrine
(0.1 mM; cat. #A0937; Sigma-Aldrich), and antibiotics. AML12
mouse hepatocytes (cat. #CRL-2254; ATCC, Manassas, VA, USA)
were cultured in DMEM/F12 medium supplemented with 10% FBS
and Insulin -Transferrin-Selenium (ITS suplement; ATCC): insulin
(0.005 mg/mL), transferrin (0.005 mg/mL), selenium (5 ng/mL),
and with dexamethasone (40 ng/mL) in the presence of antibiotics.
All cells were maintained under standard culture conditions (37C,
5% CO2, humidified atmosphere).
For the assessment of the functionality of prepared constructs, cells
were transfected with either PEI MAX (HEK293) or Lipofectamine
2000 (C2C12, HL-1, AML12) and transgene-encoding plasmid. The
functionality of scAAV vectors was tested through transduction of
target cells with multiplicity of infection (MOI) of 10,000 vg/cell.
Transgene expression was monitored up to 7 days after transduction.
In Vivo Administration of AAV Vectors
AAV vectors (scAAV9-HO1-TS and scAAV9-HO1-iTS) were
administered systemically through tail vein injection to 3-month-
old male and female HO-1 KO mice of C57BL/6J  FVB strain at
the dose of 5  1011 vg/animal. After 4 weeks, mice were euthanized
with CO2 and immediately perfused through the left ventricle with
PBS containing 0.5 U/mL heparin. Hearts, livers, and gastrocnemius
muscles were collected, snap frozen in liquid nitrogen, and stored at
80C for further analysis.
Western Blotting
Cells were washed twice with ice-cold PBS and scratched from
the plate in 1% Triton X-100 in PBS with addition of EDTA-free
cOmplete Protease Inhibitor Cocktail (cat. #11873580001; Roche,
Basel, Switzerland). After centrifugation (10,000  g, 10 min, 4C),
supernatants were collected and protein concentration was deter-
mined using DC Protein Assay (cat #5000112; Bio-Rad, Hercules,
CA, USA) according to the manufacturer’s instructions.
Samples prepared in reducing, denaturing conditions (15–30 mg of
protein) were loaded on 12% gel followed by SDS-PAGE electropho-
resis (150 V through the stacking gel, 200 V through the separating
gel). Then, wet transfer to 0.45 mm nitrocellulose membrane was per-
formed (100 V, 1 h). Next, membranes were incubated in blocking
buffer (5% nonfat dry milk in Tris-buffered saline [TBS]) for 1 h at
room temperature (RT) and transferred to solutions of primary anti-
bodies (a-tubulin antibody, clone: B-5-1-2 [Sigma-Aldrich], cat.
#T5168; HO-1 antibody, polyclonal [Enzo, Farmingdale, NY, USA],
cat. #ADI-SPA-894-F) diluted 1,000 times in blocking buffer.
Following overnight incubation at 4C, membranes were washed
five times with TBS containing 0.1% Tween 20, and subsequently sec-
ondary antibodies conjugated with horseradish peroxidase diluted in
blocking buffer were added for 1 h at RT. After repeating the washing
steps, chemiluminescent substrate was added for 5 min, and mem-
branes were manually developed.r Therapy: Methods & Clinical Development Vol. 17 June 2020 1197
Table 1. Characteristics of the Patients
Patient ID Sex Age (Years) Disease
M_63 male 63 ischemic cardiomyopathy
M_24 male 24 cardiomyopathy
M_34 male 34 restrictive cardiomyopathy
M_51 male 51 dilated cardiomyopathy
F_62 female 62 congestive heart failure
F_38 female 38 cardiomyopathy, heart failure
M_46 male 46 chronic heart failure
Molecular Therapy: Methods & Clinical DevelopmentAssessment of AAV Genome Copies in Tissues
In the first step, tissue fragments were homogenized in protein
digestion buffer (10 mM EDTA, 1% SDS, and 400 mg/mL Protein-
ase K in 500 mL TBS) and incubated for 1 h at 37C. Next, equal
volume of phenol-chloroform-isoamyl alcohol (25:24:1, cat.
#P3803; Sigma-Aldrich) was added, and samples were vortexed
vigorously for 1 min. To allow separation of phases, samples
were centrifuged (12,000  g, 15 min, RT), and then the top,
aqueous phase was transferred to new tubes and subsequently
mixed with 1 mL absolute ethanol and 10 mL of 5 M NaCl.
Next, in order to enable DNA precipitation, the samples were
incubated overnight in 20C. The following day, after centrifuga-
tion (12,000  g, 15 min, RT) and washing of DNA with 70%
ethanol, samples were air-dried and resuspended in nuclease-free
water. The number of AAV genome copies in tissues was assessed
utilizing qPCR method with TaqMan probe as described in the
AAV titration procedure above and normalized to 18S rRNA
expression.
RNA Isolation, Reverse Transcription, and qPCR
Total RNA was isolated by lysing the samples in TRIzol reagent (cat.
#15596026; Thermo Fisher Scientific, Waltham, MA, USA) followed
by phenol-chloroform extraction and isopropanol precipitation. For
analysis of gene expression, synthesis of cDNA was conducted with
RevertAid reverse transcriptase (cat. #EP0441; Thermo Fisher Scien-
tific) according to manufacturer’s instructions using 1 mg RNA. qPCR
was performed using StepOne Plus Real-Time PCR (Applied Bio-
systems, Foster City, CA, USA) with reaction mix composed of
SYBR Green PCR Master Mix (SYBR Green JumpStart Taq, cat.
#S4438; Sigma-Aldrich), 20 ng of a template, and transgene-specific
primers (final concentration 500 nM; Table 1). Elongation factor 2
(EEF2, Eef2) served as a housekeeping gene in all mRNA expression
analyses. Primer sequences were as follows: EF2 For: 50-TCAGCAC
ACTGGCATAGAGG-30, Rev: 50-GACATCACCAAGGGTGTGCA-
30; HMOX1 (HO-1) For: 50-GGAGGTCATCCCCTACACAC-30,
Rev: 50-CTGGGAGCGGGTGTTGAGTG-30; HNF1a For: 50-ACA
GCTTGGAGCAGACATCC-30, Rev: 50-CTGCTTGGTGGGCGTG
AG-30; HNF3b (FOXA2) For: 50-AATCTCAGCCTCCCAACCGTC-
30, Rev: 50-CGGCGTTCATGTTGCTCAC-30; RXRA For: 50-CATTT
CCTGCCGCTCGATTT-30, Rev: 50-GCTGACGGGGTTCATAGG
TG-30; 18S rRNA For: 50-CCAGAGCGAAAGCATTTGCCAAGA-
30, Rev: 50-GCATTGCCAGTCGGCATCGTTTAT-30.1198 Molecular Therapy: Methods & Clinical Development Vol. 17 JuneIn case of miRNA expression analysis, miRCURY LNA RT Kit (cat.
#339340; QIAGEN, Hilden, Germany) was utilized for reverse tran-
scription together with compatible miRCURY LNA miRNA PCR
Assay (cat. #339345; QIAGEN) and predesigned locked nucleic acid
(LNA) primers (QIAGEN) recognizing miRNA-122-5p (cat.
#MS00003416), miRNA-206-5p (cat. #MS00003787), and U6 small
nuclear RNA (snRNA; cat. #MS00033740); the last one was used
for normalization of the results. Analysis of melt curves, in order to
ensure specificity of the products, was conducted using StepOne Soft-
ware v.2.3.
ELISA
Fragments of tissues (heart, liver, and skeletal muscle) were homoge-
nized in 1% Triton X-100 in PBS with addition of EDTA-free
cOmplete Protease Inhibitor Cocktail using TissueLyser homogenizer
(QIAGEN). Protein concentration was determined using DC Protein
Assay according to the manufacturer’s instructions. Human HO-1
level was assessed using Simple Step ELISA (cat. #ab207621; Abcam,
Cambridge, UK) in samples diluted to match the assay’s dynamic
range, according to the manufacturer’s instructions.
Patient Samples
Heart tissue was obtained from the left ventricle of seven patients
suffering from various cardiomyopathies who were undergoing heart
transplantation surgery, under approval of the Institutional Review
Board and Bioethical Committee and with informed consent, in
accordance with the Declaration of Helsinki. The characteristics of
patients from whom the material was collected and used in this study
are provided in Table 1. Tissue fragments were stored for 24 h in
RNAlater solution (cat. #AM7020; Thermo Fisher Scientific) at 4C
and then transferred to 80C for further storage.
Differentiation of Human iPSC-Derived Cardiomyocytes
Peripheral blood mononuclear cells (PBMCs) were isolated from
three healthy volunteers under approval of the Institutional Review
Board and Bioethical Committee and with informed consent, in
accordance with the Declaration of Helsinki. The characteristics of
these donors are provided in Table 2.
PBMCs were reprogrammed to iPSCs with use of non-integrating
Sendai vectors (Cytotune-iPS 2.0 Sendai Reprogramming kit, cat.
#A16517; Thermo Fisher Scientific) according to the manufacturer’s
protocol. The pluripotency of all generated human iPSC lines was
confirmed (data not shown) as described by us previously54 prior to
using the cells in further experiments.
Human iPSCs were cultured on Geltrex-coated 12-well plates (Gel-
trex LDEV-Free hESC-Qualified Reduced Growth Factor Basement
Membrane Matrix, cat. #A1413302; Thermo Fisher Scientific) in
Essential 8 medium (cat. #A1517001; Thermo Fisher Scientific) and
passaged using 0.5 mM EDTA. The ROCK inhibitor Y-27632 (cat.
#ab120129; 10 mM; Abcam) was added to the culture medium for
the first 24 h after passage. Differentiation toward cardiomyocytes
was performed according to the protocol published by Lian et al.552020
Table 2. Characteristics of the iPSC Donors
ID Sex Age (Years)
Donor 1 male 55
Donor 2 male 48
Donor 3 male 70
www.moleculartherapy.orgParticularly, CHIR99021 (cat. #SML1046-5MG; 8–12 mM optimized
independently for each cell line; Sigma-Aldrich) and IWR-1 (cat. #
I0161-5MG; 5–7 mM; Sigma-Aldrich) were used as small molecules
regulating theWNT pathway. Cells were subjected to metabolic selec-
tion from days 10 to 16 by culture in medium consisting of RPMI
1640 without glucose supplemented with 2% B-27 supplement (cat.
#17504044; Thermo Fisher Scientific) and 4 mM sodium DL-lactate
(cat. #L1375-500ML; Sigma-Aldrich), followed by passage and
further culture until days 20–30 in RPMI 1640 containing 2% B27
supplement. All cells were maintained in a humidified tissue culture
incubator at 37C and 5% CO2.
Phenotyping of Human iPSC-Derived Cardiomyocytes
Differentiated human iPSC-derived cardiomyocytes were detached
from a culture surface with use of TrypLE Select Enzyme (cat.
#A1217701; Thermo Fisher Scientific) to obtain single-cell suspen-
sion. After washing with PBS containing 2% FBS, cells were fixed
and permeabilized using BD IntraSure Kit (cat. #641778; Becton
Dickinson, NJ, USA), followed by 45-min incubation with primary
antibodies recognizing cTnT (Cardiac Troponin T Monoclonal Anti-
body, 1:1,000, clone 13-11; cat. #MA512960; Thermo Fisher Scienti-
fic). Subsequently, the antibodies were washed out, and the cells were
incubated for 20 min with secondary antibodies conjugated with
Alexa Fluor 488 [Rabbit anti-Mouse IgG (H+L), Superclonal Recom-
binant Secondary Antibody, 1:500; cat. #A27023; Thermo Fisher Sci-
entific]. Nuclei were counterstained with 0.2 mg/mL DAPI (cat.
#D9542; Sigma-Aldrich).
All iPSC lines displayed successful cardiomyocyte differentiation with
spontaneous beating and between 55% and 89.6% cTnT+ cells (Fig-
ure S2) as determined by flow cytometric analysis using LSRFortessa
flow cytometry analyzer (BD Biosciences) and BD FACSDiva Software.
Transduction of Human iPSC-Derived Cardiomyocytes
Differentiated human iPSC-derived cardiomyocytes were treated
with neuraminidase type III (50 mU/mL, cat. #11080725001;
Sigma-Aldrich) for 2 h to expose AAV9 receptor (N-linked galac-
tose)34 on the surface of the cells and were subsequently transduced
with MOI = 104 vg/cell of either scAAV9-GFP-TS or scAAV9-
GFP-iTS vector. After 96 h, the number of GFP+ cells and MFI
were analyzed using LSRFortessa flow cytometry analyzer (BD Biosci-
ences) with BD FACSDiva Software.
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